Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II single-arm study of atezolizumab after concurrent chemoradiotherapy in unresectable stage III non-small cell lung cancer
CTR20221083Phase 2Completed
- Sponsor
- Roche
- Start
- Oct 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of atezolizumab in non-small cell lung cancer (NSCLC), sponsored by Roche. Started Oct 2022; status: completed.
02
Drugs
atezolizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20221083.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20221083.